Top Markets
Coin of the day
Adagio Therapeutics, Inc. Adagio Therapeutics, Inc.

Adagio Therapeutics, Inc.

ADGI
Pozycja w akcjach #16422
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily... Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily focused on the discovery, development, and subsequent commercialization of antibody-based therapeutics designed to combat infectious diseases across the United States. Its most advanced product candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical trials. This antibody is being evaluated for both the treatment and prevention of coronavirus disease. Adagio Therapeutics also engages in strategic collaborations. It partners with Adimab, LLC to facilitate the discovery and optimization of novel proprietary antibodies. Furthermore, the company works with the Scripps Research Institute on research initiatives aimed at identifying vaccine candidates that could prevent, diagnose, or treat influenza and beta coronaviruses. Founded in 2020, Adagio Therapeutics maintains its headquarters in Waltham, Massachusetts.
Cena akcji
$4.64
Ostatnia synchronizacja: 2022-09-12
Kapitalizacja rynkowa
$293.43M
Zmiana (1 dzień)
0.87%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Adagio Therapeutics, Inc. (ADGI)

Kategoria

Wskaźnik P/B dla Adagio Therapeutics, Inc. (ADGI)
Wskaźnik P/B na dzień 2026 TTM: 0
Według najnowszych raportów finansowych i ceny akcji Adagio Therapeutics, Inc., obecny wskaźnik P/B (TTM) wynosi 0. Na koniec 2026 wynosił 0.
Historia wskaźnika P/B dla Adagio Therapeutics, Inc. od 2026 do 2026
Wskaźnik P/B na koniec każdego roku
Rok Wskaźnik P/B Zmień
Za mało danych dla podanych dat.
Wskaźnik P/B dla podobnych firm lub konkurentów
Firma Wskaźnik P/B Różnica wskaźnika P/B Kraj
6.828 -
US
7.5116 -
NL
8.2199 -
US
3.9942 -
AU
- -
CH